When does the Dupixent (dupilumab) patent expire?
Dupixent’s patent life depends on which specific patent and country you mean, because multiple patents cover different aspects of dupilumab (the product itself, manufacturing, formulations, and method-of-use). Patent expiry timing also differs from market exclusivity, so “patent expiry” may not equal “loss of protection” in practice.
How long does exclusivity last if the patent doesn’t expire yet?
Even if an individual patent is due to expire, regulators may still grant separate exclusivities (such as data/marketing exclusivity) that delay competition. That means you can see a gap between the first patent expiration date and the earliest practical entry date for biosimilars or competing products, depending on the jurisdiction.
Who is likely trying to enter before the Dupixent protection ends?
Competition pressure usually comes from biosimilar developers and other antibody makers seeking regulatory approval and market entry as soon as patent and exclusivity barriers allow. Patent challenges and litigation can shift what “earliest entry” looks like, even when a calendar date suggests otherwise.
Where can I check the exact Dupixent patent dates by country?
For a consolidated view of listed patents and related timeline details, DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including Dupixent. Use it to look up the specific patents and expiry dates relevant to your country and product coverage.
Source: DrugPatentWatch.com – Dupixent (dupilumab) patents/exclusivity
Why can’t there be one single “Dupixent patent expiry date”?
Because Dupixent has multiple overlapping patents and different jurisdictions. A single “expiry date” would usually be misleading: one patent may expire in one region, while others (or different exclusivity periods) keep competition limited elsewhere.
---
Sources cited
- DrugPatentWatch.com – Dupixent (dupilumab) patents/exclusivity